Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

NCT00658671 is registered in ClinicalTrials.gov with CASI pharmaceuticals, Inc. as lead sponsor.

NCT NCT00658671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00658671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
Lead sponsor
CASI pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
June 30, 2012
Enrollment
67 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer